6.7 C
Saturday, April 10, 2021

Egypt to produce up to 80 million doses of Sinovac vaccine per year

Must read

UK Time Newshttps://www.uktimenews.com
UK Time News is your daily dose of Latest News, Entertainment, Music, Fashion, Lifestyle, World, Cricket, Sports, Politics, Tech, Business News Website. We provide you with the Latest Breaking News Straight from the UK & all around the World on different categories.

Thu 2021-04-08 19:23

CAIRO: Egypt has agreed with Chinese company Sinovac Biotech Ltd. to manufacture its COVID-19 vaccine in the country and could produce up to 80 million doses per year, the health ministry said Thursday.
The deal could provide a major boost to vaccination efforts in Egypt, which has a population of 100 million and has so far received just 1.5 million doses.
The Egyptian cabinet and presidency have approved a joint manufacturing agreement to manufacture the vaccines that will be distributed in Egypt and other African countries, Zayed said.
One production facility can produce 20 million doses per year, while another could produce 60 million, the health ministry said in a statement.
Egypt has so far received 854,400 doses of the vaccine produced by AstraZeneca as well as another 650,000 of the Chinese vaccine developed by the China National Pharmaceutical Group (Sinopharm). The number of Sinopharm doses received will soon increase to 1 million, Zayed said.
Egypt began vaccinating frontline medical personnel against COVID-19 on January 24 and expanded its deployment on March 4 to include the elderly and those with chronic illnesses.

READ  Ald. James Gardiner denies a parking permit exception for residents of the building on the northwest side; Owners believe retaliation for social media posts
READ  Government appreciates the growing importance of tudung for Muslims, considering how nurses can wear it with uniforms: PM Lee
Main category:
Middle East

Egypt will “ make every effort ” to help resolve the crisis in Lebanon, with Egyptian puppet Abla Fahita posing for sportswear giant Adidas.

More articles


Latest article